Abstract: A system configured to generate images includes one or more narrowband electromagnetic sources configured to emit a first radiation and a second radiation. The system also includes a detector configured to detect first reflected radiation off of an object and second reflected radiation off of the object, where the first reflected radiation results from the first radiation and the second reflected radiation results from the second radiation. The system further includes a processor operatively coupled to the detector and configured to generate an image of the object based at least in part on a first amplitude of the first reflected radiation and a second amplitude of the second reflected radiation. The processor is also configured to determine a depth profile of the object based at least in part on the first reflected radiation and the second reflected radiation detected by the detector.

Abstract: The present disclosure generally relates in certain embodiments to a combined cycle power plant system comprising an electrochemical compressor. For instance, in one set of embodiments, the electrochemical compressor is may separate oxygen from a flow of air from an air source to provide a pressurized flow of oxygen to a combustor. In some embodiments, the resulting combustion products may only include oxygen and water without any substantial fraction of other combustion products or contaminants which may facilitate the separation of carbon dioxide (CO2) for subsequent processes including compression and/or storage.

Abstract: Provided are actuation devices, virtual reality devices formed from the actuation devices, and related virtual reality methods. The devices may comprise a plurality of spatially distributed actuators, each actuator configured for interacting with a biological skin surface; a wireless controller configured to receive operative command signals to control each of the actuators; and a wireless power system to power the actuators. Also provided are unique layouts of multiple interconnected devices to achieve large area coverage.

Abstract: An accelerated aging circuit is described to shorten the required stress time to a few seconds of operation. Due to the challenges posed by process variation in advanced CMOS technology, a stochastic processing methodology is also described to reduce the failure rate of the tracking and detection. Combining both circuit and system level acceleration, the creation of a silicon marker can be realized within seconds of usage in contrast with days of operation from previously reported aging monitor.

Abstract: Methods for making porous polyelectrolyte complex (PEC) films are provided. In an embodiment, such a method comprises coating the surface of a substrate with a polyelectrolyte (PE) coacervate mixture, the PE coacervate mixture comprising a cationic polymer, an anionic polymer, water, and a salt, the PE coacervate having a salt concentration; exposing the coating to an aqueous medium having another salt concentration, for a time to induce solidification of polyelectrolyte complexes (PECs) in the form of a PEC film having pores distributed throughout, wherein a difference ??C-M #191 between the salt concentration of the PE coacervate mixture and the salt concentration of the aqueous medium is selected to achieve a predetermined porosity for the porous PEC film.

Abstract: Representative methods, apparatus and systems are disclosed for blood pressure and other vital sign monitoring using arterial applanation tonometry, including ambulatory blood pressure and other vital sign monitoring. A representative system comprises a wearable apparatus. The various embodiments measure blood pressure and other vital sign monitoring using a plurality of pressure sensors of a pressure sensor array, with one or more of the pressure sensors 140 applanating an artery, such as a radial artery. In a first embodiment, a pressure sensor signal is utilized which has the highest cross-coherence with the signals of its nearest pressure sensor neighbors of the pressure sensor array. In a second embodiment, Kalman filtering is utilized for the pressure sensor signals from the pressure sensor array.

Abstract: By a genome-wide gene analysis of expression profiles of known or putative gene sequences in peripheral blood and biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing liver transplantation patients who have Acute Rejection (AR), Hepatitis C Virus Recurrence (HCV-R), both AR/HCV-R, or Acute Dysfunction No Rejection (ADNR). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of liver transplantation patients.

Abstract: The invention relates to a host material for stabilizing a Li metal electrode, fabricating methods and applications of the same. The host material includes crumpled graphene balls operably defining a scaffold having volumes and voids inside and in between the crumpled graphene balls so as to allow uniform and stable Li deposition/dissolution inside and in between the crumpled graphene balls without electrode volume fluctuations or with sufficiently small electrode volume fluctuations. The crumpled paper ball-like structures of graphene particles can readily assemble to yield the scaffold with scalable Li loading up to 10 mAh cm-2 within tolerable volume fluctuations. High Coulombic efficiency of 97.5% over 750 cycles (1500 hours) is achieved. Plating/stripping Li up to 12 mAh cm-2 on the crumpled graphene scaffold does not experience dendrite growth.

Abstract: Systems for coherent light detection are provided, including a system comprising a light source configured to generate light; a first optical assembly configured to split the light into a reference arm and a sample arm; a second optical assembly configured to illuminate a sample with light of the sample arm, thereby generating a sample signal; a third optical assembly configured to combine the sample signal with light of the reference arm, thereby generating an interference signal; and a detector assembly comprising an array of carrier injection photodetectors, the array arranged to collect the interference signal. Methods of using the systems are also provided.

Abstract: A virtual reality (VR) olfactory apparatus includes an odorant saturation chamber having an inlet and an outlet. At least a portion of the odorant saturation chamber includes a plurality of beads and a liquid. The liquid includes an odorant concentrate. The inlet extends into this portion of the odorant saturation chamber. The VR apparatus also includes a mass flow controller to generate an air flow to the inlet of the odorant saturation chamber such that the air flow passes through the portion of the odorant saturation chamber to form an odorant. The air flow passes the odorant through the outlet of the odorant saturation chamber. The VR apparatus further includes a nose chamber connected to the outlet and configured to receive the odorant.

Abstract: Provided herein are substituted haloimidazole crystals, the substituted haloimidazole crystal comprising a substituted haloimidazole compound wherein the substituents are selected from the group consisting of hydrogen, an alkyl, and a halogen. The substituted haloimidazole crystals may further comprise second substituted haloimidazole. The substituted haloimidazole crystals may be piezoelectric, ferroelectric, flexible, or any combination thereof. Also provided herein are methods for preparing substituted haloimidazole crystals.

Abstract: Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

Abstract: Composites comprising anode and cathode active materials conformally coupled to few-layered graphene, corresponding electrodes and related methods of preparation.

Abstract: A medicine container includes a controller and a scale connected with the controller. The scale is configured to measure a weight of a content contained in the medicine container. An inertial measurement unit connects with the controller. The inertial measurement unit is configured to detect a position of the medicine container. The controller is configured to process the position information to ensure that the container is located in an upright position before the weight measurement is considered.

Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.

Abstract: Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII (1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke.

Abstract: Provided herein are small unilamellar vesicles with surface-displayed polymer moieties, and methods of use and manufacture thereof. In particular, provided herein are polymer-grafted nanobins, and methods of drug delivery therewith.

Abstract: A rolling mill system for Incremental rotary shaping of an elongated workpiece is provided that includes first and second workpiece holders. A support frame has a track with the first and second workpiece holders being movably associated with the track, the workpiece holders and an associated workpiece being movable in unison along the track. A radial chuck is mounted to the frame that includes a plurality of jaws that are movable radially inwardly and outwardly. Each jaw has a tool mounted thereto that is rotatable about an axis of rotation, with the axis of rotation of each tool being oriented at a skew angle relative to the longitudinal axis of a workpiece. A source of electric current and an electrically conductive flow path are provided for flowing electrical current through a workpiece. A controller is provided that is configured to control the operation of each of the first motor, second motor and third motor, and to control the flow of current flowing through the tools to the workpiece.

Abstract: Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid-amino transferase (GABA-AT) activity and ornithine aminotransferase (OAT) activity. Some of the enantiomerically pure compounds inhibit OAT activity more potently than the racemic compound. The disclosed compounds may be used to selectively inhibit OAT activity, for example, to treat hepatocellular carcinoma and/or used to selected inhibit GABA-AT activity, for example, to treat neurological diseases and disorders.

Abstract: Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.